We've set aside this episode to review not one, not two, but three 5-stock samplers from the last three years. What stocks did we pick? How did they perform? And most importantly, what can we learn from the discipline of keeping score?
It’s the fourth or maybe fifth annual Loofie Awards where we celebrate the best (but this year mostly the worst) in business and finance. We’ll say goodbye to some truly horrible CEOs, say hello to some comeback kids, and give awards for Best Number and more.
Amazon rebuffs the Big Apple. Coke fizzles while Pepsi sparkles. And NVIDIA stops the bleeding. Analysts Andy Cross, Ron Gross, and Jason Moser discuss those stories and talk Activision Blizzard, Shopify, Restaurant Brands International, and UnderArmour. Plus, corporate governance expert and film critic Nell Minow talks about the problem with stock buybacks and previews the Oscars.
Thanks Audible! Get Power Moves by Adam Grant for free when you sign up for a free Audible trial at Audible.com/foolpower or text “foolpower” to 500 500.
Texas Roadhouse posts solid comps growth in the 4th quarter. David Kretzmann analyzes why the management team is just one reason he likes this restaurant. Plus, we discuss Tesla’s latest executive departure and dip into the Fool Mailbag. To check out the new offering from Motley Fool Singapore that David mentioned just go to www.fool.sg/malaysia.
Some medical device companies hold such a strong competitive position in their industry that it isn't a stretch to call them a monopoly.In this week's episode, Motley Fool Contributor Brian Feroldi and Industry Focus host Shannon Jones discuss why Intuitive Surgical, Abiomed, and Novocure are three medical device monopolies hiding in plain sight.
Get more great information on becoming a better investor -- free and straight to your inbox!
Privacy/Legal Information.
By submitting your email address, you consent to us keeping you informed about updates to our website and about other products and services that we think might interest you. You can unsubscribe at any time. Please read our Privacy Statement and Terms & Conditions.
REVIEWAPALOOZA!: Three 5-Stock Samplers
We've set aside this episode to review not one, not two, but three 5-stock samplers from the last three years. What stocks did we pick? How did they perform? And most importantly, what can we learn from the discipline of keeping score?
Feb 20, 2019 • 51:09 • Rule Breaker Investing
Listen